Interim revenue was 1,167,233 million yen, up 19.7% year-over-year. Core operating profit was 221,331 million yen, up 46.9%; operating profit was 193,795 million yen; interim profit was 151,534 million yen. For fiscal 2027 the dividend policy anticipates a full-year dividend of 100 yen including a 50 yen interim dividend. Supplementary earnings materials are available and an earnings presentation will be held.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4568","jir_company_name":"Daiichi Sankyo Company, Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4568-20261030-01.pdf","jir_short_summary":"Interim revenue was 1,167,233 million yen, up 19.7% year-over-year. Core operating profit was 221,331 million yen, up 46.9%; operating profit was 193,795 million yen; interim profit was 151,534 million yen. For fiscal 2027 the dividend policy anticipates a full-year dividend of 100 yen including a 50 yen interim dividend. Supplementary earnings materials are available and an earnings presentation will be held.","jir_summary":"### Business Performance Overview\nFor the interim period, consolidated revenue was 1,167,233 million yen (Year-over-Year +19.7%), core operating profit was 221,331 million yen (+46.9%), and operating profit was 193,795 million yen (+34.4%). Currency effects and growth across product portfolios contributed to the results. By segment, the oncology business made a major contribution, and other units including EU Specialty and ASCA also performed solidly. Research and development expenditures expanded. Supplementary earnings materials and an earnings presentation are provided.\n\n### Shareholder Returns and Financial Position\nCash and cash equivalents increased at the interim period end; total assets were 4,258,600 million yen, and some treasury shares have been cancelled. The full-year dividend for fiscal 2026 is planned at 100 yen, with an interim dividend of 50 yen to be paid. Results of treasury share cancellations are reported, and the shareholder return policy as part of capital policy is being continued.","jir_financial_highlights":"Revenue: 1,167,233 million yen (Year-over-Year +19.7%)\nCore Operating Profit: 221,331 million yen (Year-over-Year +46.9%)\nOperating Profit: 193,795 million yen (Year-over-Year +34.4%)\nInterim Profit: 151,534 million yen (Year-over-Year +15.8%)\nNet Income Attributable to Owners of Parent (Interim): 151,534 million yen (Year-over-Year +16.3% (note: as stated in the earnings report tables))","jir_category":"","jir_hashtags":"#DaiichiSankyo, #Earnings, #Interim, #ShareholderReturns","jir_key_figures":"Revenue: 1,167,233 million yen (Year-over-Year +19.7%)\nCore Operating Profit: 221,331 million yen (Year-over-Year +46.9%)\nOperating Profit: 193,795 million yen (Year-over-Year +34.4%)","jir_meta_title":"Daiichi Sankyo Company, Limited \u2014 Financial Summary for Six Months Ended March 2027\uff5cRevenue 1,167,233 million yen, Net Income Growth","jir_meta_description":"Analysis of Daiichi Sankyo's consolidated financial summary for the six months ended March 2027 (IFRS). Revenue rose 19.7% year-over-year to 1,167,233 million yen, and core operating profit increased 46.9% to 221,331 million yen. Key points on dividend policy, financial position and segment trends.","jir_og_title":"Daiichi Sankyo \u2014 Six Months Financial Summary\uff5cRevenue 1,167,233 million yen","jir_og_description":"Daiichi Sankyo's interim results: revenue 1,167,233 million yen, core operating profit 221,331 million yen, and a dividend policy targeting 100 yen per year. Detailed financial position and shareholder returns discussed.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026\/04-09\\\",\\\"2027\/04-09\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[975353,1167233]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Core Operating Profit Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026\/04-09\\\",\\\"2027\/04-09\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Core Operating Profit\\\",\\\"data\\\":[150690,221331]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Margin Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026\/04-09\\\",\\\"2027\/04-09\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Margin\\\",\\\"data\\\":[15.0,16.0]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Japan\\\",\\\"Oncology\\\",\\\"EU Specialty\\\",\\\"ASCA\\\"],\\\"datasets\\\":[{\\\"data\\\":[2327,4226,809,1425]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Full-Year Guidance vs Actual Comparison\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Revenue\\\",\\\"Operating Profit\\\",\\\"Profit for the Period\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"2026 Actual\\\",\\\"data\\\":[9753,1506,130.8]},{\\\"label\\\":\\\"2027 Forecast\\\",\\\"data\\\":[2340,320,251]}]},\\\"options\\\":{}}\"}]","ir_related_company":6853,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-137316","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n